Immuno-Oncology. Glioblastoma 3 November 2016 Zurich, Switzerland

Size: px
Start display at page:

Download "Immuno-Oncology. Glioblastoma 3 November 2016 Zurich, Switzerland"

Transcription

1 ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma 3 November 2016 Zurich, Switzerland Michael Weller Department of Neurology & Brain Tumor Center University Hospital Zurich Frauenklinikstrasse 26 CH-8091 Zurich michael.weller@usz.ch

2 Disclosures Research grants: Acceleron, Actelion, Bayer, Isarna, MSD, Merck & Co, Novocure, Piqur, Roche Honoraria for lectures or advisory board participation or consulting: BMS, Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva

3 Case Report 60 years old male patient Diagnosis of glioblastoma in the left temporal lobe 3/2014 IDH1 wild-type; MGMT promoter unmethylated 3/2014 biopsy 4-5/2014 TMZ-based radiochemotherapy 6-11/ cycles of maintenance TMZ 11/2014 tumor progression enrolment CA

4 9/2014 During maintenance TMZ 11/2014 Tumor progression Start Nivolumab 3/2015 (Pseudo-)progression? Decision to continue nivolumab treatment

5 6/2015 Nivolumab 8/2015 2/2016 7/2016

6 Case Report Patient on nivolumab for 21 months (ongoing) Clinically stable Nivolumab is well tolerated SAE: pulmonary embolism 11/2015 (rather unrelated to study drug)

7

8

9 Immunosuppression in glioblastoma: challenging a popular assumption The brain is an immunoprivileged site: is there need for additional immunosuppression? Glioblastoma cells (may) lack tumor-specific antigens: why additional suppression of a blinded immune system? Is there evidence that immune surveillance accounts for the low incidence of systemic metastasis in glioblastoma? The increased incidence of glioblastoma in the elderly may relate to immune senescence, but why is there no increased risk with immunodeficiency states including AIDS?

10 Current approaches of immunotherapy for glioblastoma Ipilimumab (anti-ctla-4) (Yervoy, BMS) Pembrolizumab (anti-pd-1) (Keytruda, MSD) Nivolumab (anti-pd-1) (Opdivo, BMS) Atezolizumab (anti-pd-l1) (Roche) TGF-β antisense oligonucleotide (Trabedersen, Antisense Pharma/Isarna) TGF-β receptor antagonists (LY , Galunisertib, Lilly) Vaccination against EGFRvIII (Rindopepimut, Rintega, Celldex) DC/peptide-based immunotherapy (ICT-107, Immunocellular) DC/lysate-based immunotherapy (DCVax, NW Biotherapeutics) Personalized multipeptide vaccination (IMA950, Immatics GAPVAC) DC/CMV-targeted immunotherapy (Duke) IDH-targeted immunotherapy (Heidelberg, and others) Chimeric antigen receptor (CAR) therapy (e.g., EGFRvIII)

11 Expression and prognostic role of PD-L1 in glioblastoma

12 Current status of the PD-1/PD-L-1 axis in glioblastoma PD-L1 is expressed in human glioblastoma in vivo TCGA and other public data bases do not define a major prognostic role for PD-L1 expression in glioblastoma The significance as a biomarker of tumoral versus nontumoral PD-L1 expression remains to be determined in glioblastoma, like in many other cancers Preclinical studies demonstrate activity of PD-1 inhibition in rodent glioma models

13 Current approaches of immunotherapy for glioblastoma CheckMate 143

14 CheckMate 143 Transition from phase II to III

15 Trial name / ClinicalTrials.gov Identifier Target population Treatment arms Phase Primary endpoint Status (as per March 2016) CheckMate 143 NCT First recurrence of glioblastoma Experimental: nivolumab Comparator: bevacizumab III OS Accrual completed CheckMate 498 NCT Newly diagnosed glioblastoma Unmethylated MGMT promoter Experimental: RT + nivolumab Comparator: TMZ/RTTMZ III OS Not yet recruiting CheckMate 548 NCT Newly diagnosed glioblastoma Methylated MGMT promoter Experimental: TMZ/RTTMZ + nivolumab Comparator: TMZ/RTTMZ + placebo II OS Not yet recruiting NCT Newly diagnosed or recurrent glioblastoma requiring surgery Nivolumab (neoadjuvant, before surgery) II PD-L1 expression (lymphocytes, tumor) Recruiting NCT Newly diagnosed glioblastoma Arm 1: TMZ + ipilimumab Arm 2: TMZ + nivolumab Arm 3: TMZ + ipilimumab + nivolumab I MTD (ipilimumab, nivolumab, combination) Recruiting NCT Recurrent high grade glioma Hypofractionated stereotactic re- RT + bevacizumab + pembrolizumab I MTD (pembrolizumab) Recruiting NCT Recurrent glioblastoma Cohort A: pembrolizumab + bevacizumab Cohort B: pembrolizumab II Cohort A: PFS-6 Cohort B: MTD (pembrolizumab) Not recruiting NCT Recurrent glioblastoma Pembrolizumab II PFS-6 Recruiting NCT NCT Recurrent glioblastoma, hypermutator phenotype Newly diagnosed or recurrent glioblastoma Pembrolizumab n/a Response rate Recruiting MEDI4736, Bevacizumab + MEDI4736, RT + MEDI4736 II OS-12, PFS-6, OS-6 (depending on treatment) Recruiting

16 Immunosuppression in the glioblastoma microenvironment Nduom et al. Neuro-Oncology 2015:17:vii9-vii14

17 Current approaches of immunotherapy for glioblastoma Ipilimumab (anti-ctla-4) (Yervoy, BMS) Pembrolizumab (anti-pd-1) (Keytruda, MSD) Nivolumab (anti-pd-1) (Opdivo, BMS) Atezolizumab (anti-pd-l1) (Roche) TGF-β antisense oligonucleotide (Trabedersen, Antisense Pharma/Isarna) TGF-β receptor antagonists (LY , Galunisertib, Lilly) Vaccination against EGFRvIII (Rindopepimut, Rintega, Celldex) DC/peptide-based immunotherapy (ICT-107, Immunocellular) DC/lysate-based immunotherapy (DCVax, NW Biotherapeutics) Personalized multipeptide vaccination (IMA950, Immatics GAPVAC) DC/CMV-targeted immunotherapy (Duke) IDH-targeted immunotherapy (Heidelberg, and others) Chimeric antigen receptor (CAR) therapy (e.g., EGFRvIII)

18 TGF-β and immunosuppression in glioblastoma: clinical studies

19 Current approaches of immunotherapy for glioblastoma Ipilimumab (anti-ctla-4) (Yervoy, BMS) Pembrolizumab (anti-pd-1) (Keytruda, MSD) Nivolumab (anti-pd-1) (Opdivo, BMS) Atezolizumab (anti-pd-l1) (Roche) TGF-β antisense oligonucleotide (Trabedersen, Antisense Pharma/Isarna) TGF-β receptor antagonists (LY , Galunisertib, Lilly) Vaccination against EGFRvIII (Rindopepimut, Rintega, Celldex) DC/peptide-based immunotherapy (ICT-107, Immunocellular) DC/lysate-based immunotherapy (DCVax, NW Biotherapeutics) Personalized multipeptide vaccination (IMA950, Immatics GAPVAC) DC/CMV-targeted immunotherapy (Duke) IDH-targeted immunotherapy (Heidelberg, and others) Chimeric antigen receptor (CAR) therapy (e.g., EGFRvIII)

20

21 Coexpression of wild-type EGFR and EGFRvIII expression in glioblastoma EGFRwt (3C6) GB 1097 EGFRvIII (L8A4) Overlap GB 1097 GB 1122

22 Rindopepimut (CDX-110) Vaccine designed to generate a specific immune response against EGFRvIII-expressing tumors Off the shelf vaccine recognized across HLA types Consists of the EGFRvIII antigen (unique 13 amino acid peptide sequence) chemically conjugated to Keyhole Limpet Hemocyanin Delivered as intradermal injection of 500ug rindopepimut with 150ug GM-CSF as an adjuvant Stable, lyophilized formulation LEEKKGNYVVTDHC O S N O O N KLH >30

23 Progression-free survival (from diagnosis) Survival Probability p = 0.44 Median (months) Comparison to Historical Control ACT III (n=65) 12.3 p = ACT II (n=22) 15.3 p = ACTIVATE (n=18) 14.2 p = Matched historical control (n=17) 6.4 PFS from diagnosis (months) ACT III Primary Endpoint Progression-free survival (PFS) at 5.5 months from vaccination ( 8.5 months from diagnosis): PFS = 66% p = vs. null hypothesis (H 0 ) 53% Vaccinations begin approximately 3 months after diagnosis

24 Overall survival (from diagnosis) Median (months) OS at 24 Months OS at 36 Months Comparison to Historical Control Survival Probability p = 0.46 ACT III (n=65) % 31% p = < ACT II (n=22) % 23% p = ACTIVATE (n=18) % 33% p = Matched historical control (n=17) % 6% OS from diagnosis (months) Vaccinations begin approximately 3 months after diagnosis Median duration of follow-up: ACT III: 48.7 months ACT II: 71.8 months ACTIVATE: 99.3 months

25 Does Rindopepimut mediate EGFRvIII elimination at recurrence? Pre-Vaccine Primary Tumor Post Vaccine Recurrent Tumor EGFRvIII was selectively eliminated in recurrent tumors for 26/32 (81%) patients across all three studies 15/15 control patients treated with RT/TMZ (+/- CPT-11, bevacizumab or erlotinib) were EGFRvIII(+) at recurrence Robust anti-egfrviii titers in most patients; titers maintained for > 6 months following cessation of treatment 1. Mehta, et. al. JCO 2011

26 ACT IV Study Design R A N D O M I Z A T I O N Vaccine Priming D1 D15 C1D1 C1D22 Adjuvant Temozolomide and Vaccine Therapy (TMZ-V, 6-12 cycles) Vaccine Maintenance Therapy (VMT) C2D22 C3D22 etc. C1D1 C2D1 etc Follow Up Dose vaccine days 1 and 15 of Vaccine Priming cycle Start cycle within 4 days after randomization and within 7-14 days after completion of CRT Vaccine or control (KLH) is administered Day 22 of each TMZ cycle Begin TMZ no sooner than 6 days after administration of the second vaccine priming dose Begin TMZ no sooner than 28 days after completion of CRT Begin TMZ when ANC 1000/µL and platelets 100,000/µL TMZ dosed days 1-5 of each 28 day cycle If no disease progression after TMZ, continue dosing vaccine every 28 days (Day 1 ±3 days of each 28 day cycle) until intolerance or disease progression Follow-up for overall survival every 12 weeks after disease progression Temozolomide Dosing Vaccine or Control (KLH) Dosing CRT Chemoradiation Therapy Treatment will be discontinued upon disease progression, unacceptable treatment-related toxicity, or patient refusal to continue study treatment

27

28

29

30 Overall survival (from diagnosis) Median (months) OS at 24 Months OS at 36 Months Comparison to Historical Control Survival Probability p = 0.46 ACT III (n=65) % 31% p = < ACT II (n=22) % 23% p = ACTIVATE (n=18) % 33% p = Matched historical control (n=17) % 6% OS from diagnosis (months) Vaccinations begin approximately 3 months after diagnosis Median duration of follow-up: ACT III: 48.7 months ACT II: 71.8 months ACTIVATE: 99.3 months

31 Is EGFRvIII a negative prognostic biomarker? Datasets N Median overall survival (months) Overall survival at 3 years (%) EGFRvIII expression Heimberger et al. CCR <5 Pelloski et al. JCO RTOG 0525, all patients RTOG 0525, TMZ 5/ RTOG 0525, matched patients German Glioma Network All patients Matched patients ACT III (EGFRvIII vaccine)

32 Is EGFRvIII a negative prognostic biomarker? Datasets N Median overall survival (months) Overall survival at 3 years (%) EGFRvIII expression Heimberger et al. CCR <5 Pelloski et al. JCO RTOG 0525, all patients RTOG 0525, TMZ 5/ RTOG 0525, matched patients German Glioma Network All patients Matched patients ACT III (EGFRvIII vaccine)

33 ReACT Bevacizumab naïve Study vaccine + Randomization (1:1) (n=70) bevacizumab No prior bevacizumab or VEGF/ Double-blind VEGF receptor-targeted agents treatment Control + bevacizumab Bevacizumab refractory (Initial cohort: n=25 Expansion cohort: n=up to 73) Progression during or within two months of bevacizumab Open-label treatment Study vaccine + bevacizumab 33 33

34 Overall Survival Median, months (95% CI) OS 12 OS 18 OS 24 Rindopepimut + BV 11.3 (9.9, 16.2) 44% 32% 25% Control + BV 9.3 (7.1, 11.4) 32% 13% 0% HR = 0.53 (0.32, 0.88) p = * Per-protocol population analyses: HR = 0.53 (0.31, 0.90) p = * Five patients in the rindopepimut + BV arm, and 1 patient in the control + BV arm, continue survival follow-up without progression per expert review. * Log-rank test (2-sided) 34

35 Where do we go from here? Rindopepimut Bevacizumab

36

37 Current approaches of immunotherapy for glioblastoma Ipilimumab (anti-ctla-4) (Yervoy, BMS) Pembrolizumab (anti-pd-1) (Keytruda, MSD) Nivolumab (anti-pd-1) (Opdivo, BMS) Atezolizumab (anti-pd-l1) (Roche) TGF-β antisense oligonucleotide (Trabedersen, Antisense Pharma/Isarna) TGF-β receptor antagonists (LY , Galunisertib, Lilly) Vaccination against EGFRvIII (Rindopepimut, Rintega, Celldex) DC/peptide-based immunotherapy (ICT-107, Immunocellular) DC/lysate-based immunotherapy (DCVax, NW Biotherapeutics) Personalized multipeptide vaccination (IMA950, Immatics GAPVAC) DC/CMV-targeted immunotherapy (Duke) IDH-targeted immunotherapy (Heidelberg, and others) Chimeric antigen receptor (CAR) therapy (e.g., EGFRvIII)

38 ICT-107: an autologous six-antigen DC vaccine Matured, Activated, Peptide-loaded DC MHC Class I Six 9-10 amino acid antigen epitopes MAGE-1 (HLA - A1) AIM-2 (A1) gp100 (HLA - A2) IL-13Rα2 (A2) HER2/neu (A2) TRP-2 (A2) Rationale for antigen choice Targeting multiple antigens minimizes tumor escape High expression levels for all antigens on GBM samples Bias toward TAA associated with cancer stem cells Control used in Ph II Matured, activated DC without peptide loading

39

40 A phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy (STING - EORTC 1507 Alliance - ICT) Stratifications Consent HLA-A2 typing Apheresis MGMT Age No vs residual < 1 cm 3 tumor Randomize Surgery Screen MRI MGMT and enroll TMZ/RT Eligibility Confirmation MRI Vaccine Induction Phase Patient-Specific Vaccination ICT-107 or Control 1/wk for 4 wks Maintenance Phase DC therapy Maintenance Phase: Maintenance with monthly ICT-107 (patient-specific DC therapy) for 11 months, and once every 6 months thereafter Week until 2depletion or confirmation of progressive disease. CT-107 and TMZ will be administered Rest Weektwo weeks apart during cycle 1 to cycle 6 maintenance TMZ. TMZ will be given Days 1-5 ± 2 days on a 28-day cycle. Study DC therapy will be given on Day 21 ± 2 days. 40

41 Current approaches of immunotherapy for glioblastoma Ipilimumab (anti-ctla-4) (Yervoy, BMS) Pembrolizumab (anti-pd-1) (Keytruda, MSD) Nivolumab (anti-pd-1) (Opdivo, BMS) Atezolizumab (anti-pd-l1) (Roche) TGF-β antisense oligonucleotide (Trabedersen, Antisense Pharma/Isarna) TGF-β receptor antagonists (LY , Galunisertib, Lilly) Vaccination against EGFRvIII (Rindopepimut, Rintega, Celldex) DC/peptide-based immunotherapy (ICT-107, Immunocellular) DC/lysate-based immunotherapy (DCVax, NW Biotherapeutics) Personalized multipeptide vaccination (IMA950, Immatics GAPVAC) DC/CMV-targeted immunotherapy (Duke) IDH-targeted immunotherapy (Heidelberg, and others) Chimeric antigen receptor (CAR) therapy (e.g., EGFRvIII)

42 Chimaeric antigen receptor (CAR) therapy: the molecular concept CD28 4-1BB CD3ζ Heczey, Discov Med 16: , 2013

43 Does immunotherapy for glioblastoma have a future? Most promising field of cancer therapy globally Immunotherapy requires sophisticated logistics Immunotherapy is expensive Immunotherapy may only work in young patients with minimal residual tumor (?)

44 Quadrennial Meeting of the World Federation of Neuro-Oncology WFNO 2017 in conjunction with the Meeting of the European Association of Neuro-Oncology (EANO) WFNO 2017 & EANO ZURICH, SWITZERLAND Kongresshaus Zürich May 4-7, 2017 INVITATION

Immuno-Oncology. Glioblastoma and CNS tumors 5 July 2016 Siena, Italy

Immuno-Oncology. Glioblastoma and CNS tumors 5 July 2016 Siena, Italy ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma and CNS tumors 5 July 2016 Siena, Italy Michael Weller Department of Neurology

More information

Glioblastoma and CNS tumors

Glioblastoma and CNS tumors Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS

More information

Glioblastoma and CNS tumors

Glioblastoma and CNS tumors Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology

More information

RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA

RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%

More information

Pioneering vaccines that transform lives.

Pioneering vaccines that transform lives. Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme

More information

NCT HEIDELBERG NATIONAL CENTER FOR TUMOR DISEASES. Sao Paulo, Can immunotherapy be the new weapon in the treatment of gliomas?

NCT HEIDELBERG NATIONAL CENTER FOR TUMOR DISEASES. Sao Paulo, Can immunotherapy be the new weapon in the treatment of gliomas? NATIONAL CENTER FOR TUMOR DISEASES NCT HEIDELBERG Sao Paulo, 28.04.2017 Can immunotherapy be the new weapon in the treatment of gliomas? Wolfgang Wick Neurology Clinic, University of Heidelberg Neurooncology

More information

HHS Public Access Author manuscript Transl Cancer Res. Author manuscript; available in PMC 2018 October 01.

HHS Public Access Author manuscript Transl Cancer Res. Author manuscript; available in PMC 2018 October 01. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma David C. Binder 1, Erik Ladomersky 2, Alicia Lenzen 2, Lijie Zhai 2, Kristen L. Lauing 2, Sebastian D. Otto-Meyer

More information

Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO

Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO November 24, 2013 Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO Strong interim survival trend (12.0 vs 7.9

More information

Precision medicine for gliomas

Precision medicine for gliomas Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Immunotherapy and checkpoint inhibitors for gliomas

Immunotherapy and checkpoint inhibitors for gliomas Pearce et al. Neuroimmunol Neuroinflammation 2018;5:47 DOI: 10.20517/2347-8659.2018.46 Neuroimmunology and Neuroinflammation Review Open Access Immunotherapy and checkpoint inhibitors for gliomas Clairice

More information

Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles

Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer

More information

ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY

ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune

More information

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN

More information

Contemporary Management of Glioblastoma

Contemporary Management of Glioblastoma Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I

More information

Melanoma: Immune checkpoints

Melanoma: Immune checkpoints ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

2015 EUROPEAN CANCER CONGRESS

2015 EUROPEAN CANCER CONGRESS 2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor

Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical

More information

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Limited role for extended maintenance temozolomide for newly diagnosed

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

PTAC meeting held on 5 & 6 May (minutes for web publishing)

PTAC meeting held on 5 & 6 May (minutes for web publishing) PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and

More information

TGFβR1 Kinase Inhibitor

TGFβR1 Kinase Inhibitor TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Derived from Prud homme GJ 1 ; Flavell RA, et al. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience

Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Derek Wainwright, PhD Assistant Professor Departments of Neurological Surgery, Microbiology-Immunology

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014 Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer

More information

Off-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline

Off-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. / Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases

More information

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010 University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

TGFβR1 Kinase Inhibitor

TGFβR1 Kinase Inhibitor TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Prud homme GJ 1 ; Flavell RA, et al 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase 1b/2 Dose-Escalation

More information

Options for first-line cisplatin-eligible patients

Options for first-line cisplatin-eligible patients The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt

More information

Weitere Kombinationspartner der Immunotherapie

Weitere Kombinationspartner der Immunotherapie 1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for

More information

Ruolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)

Ruolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,

More information

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role

More information

Transforming science into medicine

Transforming science into medicine Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and

More information

Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy

Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics

More information

Cancer Immunotherapy Survey

Cancer Immunotherapy Survey CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

A robust new approach. A rising trend

A robust new approach. A rising trend A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective. But with the increasing incidence

More information

Developping the next generation of studies in RCC

Developping the next generation of studies in RCC Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca

More information

Overview: Immunotherapy in CNS Metastases

Overview: Immunotherapy in CNS Metastases Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris

More information

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND

More information

Immunotherapy for the Treatment of Brain Metastases

Immunotherapy for the Treatment of Brain Metastases Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy

More information

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial

More information

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and

More information

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Prostate cancer Management of metastatic castration sensitive cancer

Prostate cancer Management of metastatic castration sensitive cancer 18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial

More information

Marizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor

Marizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY Daniela Bota, MD, PhD 1, Annick Desjardins, MD,

More information

THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium

THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

New Systemic Therapies in Advanced Melanoma

New Systemic Therapies in Advanced Melanoma New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity

More information

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas

More information

Douglas Jolly Executive VP R&D Tocagen Inc.

Douglas Jolly Executive VP R&D Tocagen Inc. REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase

More information

GLIOBLASTOMA MULTIFORME. agivingsmarterguideto acceleratingresearchprogress

GLIOBLASTOMA MULTIFORME. agivingsmarterguideto acceleratingresearchprogress GLIOBLASTOMA MULTIFORME agivingsmarterguideto acceleratingresearchprogress CONTENTS Executive Summary... 4 Disease Biology... 5 Molecular Pathways and Targets... 5 Prognostic Indicators... 6 DNA Methylations

More information

Immuno-Oncology Applications

Immuno-Oncology Applications Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures

More information

Neuro-Oncology Program

Neuro-Oncology Program Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive

More information

Immunotherapy for Renal Cell Carcinoma. James Larkin

Immunotherapy for Renal Cell Carcinoma. James Larkin Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech

More information

2011 Oncology Highlights News from ASCO 2011:

2011 Oncology Highlights News from ASCO 2011: 2011 Oncology Highlights News from ASCO 2011: Malignant Glioma David A. Reardon, M.D. Clinical Director Center for Neuro-Oncology Dana-Farber Cancer Institute 450 Brookline Avenue SW-430 Boston, MA 02215

More information

Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015

Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017 GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics

More information

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures

More information

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Renal Cell Carcinoma: Systemic Therapy Progress and Promise Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.

More information

Appendices. Appendix A Search terms

Appendices. Appendix A Search terms Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

HHS Public Access Author manuscript Immunotherapy. Author manuscript; available in PMC 2015 December 16.

HHS Public Access Author manuscript Immunotherapy. Author manuscript; available in PMC 2015 December 16. Overview of current immunotherapeutic strategies for glioma Anda-Alexandra Calinescu 1, Neha Kamran 1, Gregory Baker 1, Yohei Mineharu 2, Lowenstein Pedro Ricardo 1,3, and Castro Maria Graciela *,1,3 1

More information

Radiation Therapy and Immunotherapy: New Frontiers

Radiation Therapy and Immunotherapy: New Frontiers Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures

More information

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital

More information

Current experience in immunotherapy for metastatic renal cell carcinoma

Current experience in immunotherapy for metastatic renal cell carcinoma Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,

More information

Updates in Immunotherapy for Urothelial Carcinoma

Updates in Immunotherapy for Urothelial Carcinoma Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents

More information

DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015

DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 Disclaimer Certain statements made in this presentation are forward-looking

More information

Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla.

Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla. Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla. Santander Finantial disclosure Consultor: CELGENE Research fundings:

More information

Special Situation: Brain metastases

Special Situation: Brain metastases ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

Immuno-Oncology: Essentials for Nurses in Cancer Care

Immuno-Oncology: Essentials for Nurses in Cancer Care Immuno-Oncology: Essentials for Nurses in Cancer Care BERNADINE O LEARY RN, MN, CON (C) CLINICAL EDUCATOR, EASTERN HEALTH CANCER CARE PROGRAM COURSE FACILITATOR- EASTERN HEALTH ADULT CHEMOTHERAPY COURSE

More information

Immunotherapy in Treating Nasopharyngeal Carcinoma. Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong

Immunotherapy in Treating Nasopharyngeal Carcinoma. Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong Immunotherapy in Treating Nasopharyngeal Carcinoma Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong Disclosure Received honorarium from Merck Sharp & Dohme (MSD)

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

University of Colorado Cancer Center Brain Disease Site Schema

University of Colorado Cancer Center Brain Disease Site Schema GBM FIRST LINE 18 0376/Kazia Phase 2a study (Part 1): A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC 0084 administered to patients with glioblastoma

More information

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS) Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers

More information

Media Release. Basel, 07 December 2017

Media Release. Basel, 07 December 2017 Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

Immunotherapy in non-small cell lung cancer

Immunotherapy in non-small cell lung cancer Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali

Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures

More information

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal

More information

Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.

Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series. School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:

More information